Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report

Urology Case Reports

Volumn 14, Issue , 2017, Pages 15-17

  Huang, Jeffrey ^a   Schisler, John ^b   Wong, Hing C ^c   Rosser, Charles J ^a   Sterbis, Joseph ^b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b TRIPLER ARMY MEDICAL CENTER   (United States)

^c ALTOR BIOSCIENCE CORPORATION   (United States)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Interleukin 15; Natural killer; Non muscle invasive bladder cancer

Indexed keywords

ALT 803; ANTINEOPLASTIC AGENT; BCG VACCINE; GEMCITABINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER BIOPSY; BLADDER MUCOSA; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CYSTECTOMY; CYSTOSCOPY; ERYTHEMA; FEBRILE NEUTROPENIA; HUMAN; HUMAN TISSUE; LYMPHOCYTOPENIA; MALE; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRIORITY JOURNAL; VERY ELDERLY;

EID: 85020313057     PISSN: 22144420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eucr.2017.04.015     Document Type: Article

References (6)

1. Sylvester, R.J., Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer. Int J Urol 18:2 (2011), 113–120.
2. Herr, H.W., Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 163:1 (2000), 60–61 discussion 61–2.
3. Montecino-Rodriguez, E., Berent-Maoz, B., Dorshkind, K., Causes, consequences, and reversal of immune system aging. J Clin Invest 123:3 (2013), 958–965.
4. Gomes-Giacoia, E., Miyake, M., Goodison, S., et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One, 9(6), 2014 Jun 4, e96705, 10.1371/journal.pone.0096705.
5. Waldmann, T.A., The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006), 595–601.
6. Rhode, P.R., Egan, J.O., Xu, W., et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res 4:1 (2016 Jan), 49–60.